GlassScriptPhysician profile
Roya Karbakhsh
NPI 1992905293
$5,921.84
in general payments reported to CMS, 2019-2025
21 companies · $766 in 2025
The $766 reported for 2025 was more than what 82% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,239 · 2020: $697 · 2021: $544 · 2022: $527 · 2023: $1,481 · 2024: $668 · 2025: $766.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,915.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,914.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,551.32 | 2019-2025 | Rexulti, Abilify Mycite |
| Lundbeck LLC | $651.64 | 2019-2025 | Rexulti |
| Allergan, INC. | $600.33 | 2019-2020 | |
| Corium, LLC | $596.77 | 2022-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $496.04 | 2019-2025 | Trintellix |
| Abbvie INC. | $418.35 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $371.93 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $215.81 | 2021-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $142.11 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $131.87 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $129.17 | 2023 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $121.76 | 2025 | Cobenfy |
| Axsome Therapeutics, INC. | $121.65 | 2024 | Auvelity |
| Ucb, INC. | $109.42 | 2023 | |
| Alkermes, INC. | $97.60 | 2023 | Aristada, Aristada Initio |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $51.94 | 2020 | |
| Alfasigma USA, INC. | $29.98 | 2020-2021 | |
| Arbor Pharmaceuticals, INC. | $25.66 | 2020 | |
| Supernus Pharmaceuticals, INC. | $25.61 | 2023 | Qelbree |
| Shire North American Group INC | $17.17 | 2019 | |
| Lilly USA, LLC | $15.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roya Karbakhsh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.